A large study conducted on 4601 patients with AML showed that age and performance status of the patient (host) together with other disease variables such as white blood cells (WBC) counts, disease ontogeny (primary vs. secondary), cytogenetics and FLT3 and NPM1 mutational status may predict therapy resistance [36]. The gene discussed is FLT3; the disease is acute myeloid leukemia.